A randomized clinical trial to evaluate the efficacy of catecholamine surge supression by oral azilsartan in patients with hypertensive intracerebral hemorrhage

A randomized clinical trial to evaluate the efficacy of catecholamine surge supression by oral azilsartan in patients with hypertensive intracerebral hemorrhage - A randomized trial to evaluate the efficacy of catecholamine surge supression by azilsartan in patients with hypertensive ICH

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014323

Enrollment

Registered

2014-07-01

Start date

2014-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensive intracerebral hemorrhage

Interventions

Test arm: azilsartan administration Control arm: candesartan administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 20-85 years of age Hypertensive ICH within 6h of onset No disturbance of consciousness Those who gave us consent

Exclusion criteria

Exclusion criteria: Non-hypertensive ICH Those with disturbance of consciousness Those who did not give us consent

Design outcomes

Primary

Measure	Time frame
Chronological change in plasma levels of catecholamines, renin, and aldosterone	—

Secondary

Measure	Time frame
Chronological changes in systemic blood pressure	—

Countries

Japan

Contacts

Public ContactJoji Inamasu

Fujita Health University Neurosurgery

inamasu@fujita-hu.ac.jp0562-93-9253

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026